Foreword

It gives me immense pleasure to write the book titled Trials, Tech, and Triumphs of Drug Repurposing, expertly edited by Dr. Pratik Talukder, which arrives at a pivotal moment for the biomedical sciences. In an era marked by escalating costs, prolonged development timelines, and unacceptably high rates of clinical failure, the traditional paradigm of de novo drug discovery is increasingly proving inadequate to meet urgent global healthcare needs. These constraints have compelled the biomedical research community to seek more pragmatic, efficient, and innovative strategies for therapeutic development. Among the most promising of these approaches is drug repurposing, which shifts the focus from discovering entirely new chemical entities to identifying novel clinical applications for existing, approved, or investigational drugs. Far from being a mere strategic adjustment, drug repurposing represents a fundamental evolution in how modern medicine addresses both persistent and emerging health challenges.

It is within this rapidly evolving and highly consequential scientific landscape that Trials, Tech, and Triumphs of Drug Repurposing, expertly edited by Dr. Pratik Talukder, makes a timely and substantive contribution. This volume offers a comprehensive and insightful examination of the scientific, technological, and translational dimensions of drug repurposing, seamlessly integrating foundational concepts with cutting-edge innovations. The book successfully bridges historical perspectives with contemporary methodologies, presenting a coherent narrative that reflects the maturity and growing significance of the field.

The COVID-19 pandemic served as a profound global reminder of the urgency inherent in therapeutic development. When time is of the essence, the conventional drug discovery pipeline, which often extends beyond a decade, becomes impractical. During the pandemic, the rapid evaluation of existing drugs for novel antiviral indications compellingly demonstrated the power and feasibility of repurposing strategies. By leveraging established safety profiles, known pharmacokinetics, and existing manufacturing and regulatory infrastructures, drug repurposing enabled accelerated clinical responses and reinvigorated scientific and clinical interest in this approach. Crucially, this period marked a shift away from largely serendipitous discoveries toward a more systematic, data-driven, and technology-enabled discipline.

This volume distinguishes itself through its thoughtful and rigorous exploration of that evolution. It traces the historical roots of drug repurposing from classic examples such as aspirin and metformin to the forefront of modern methodologies driven by artificial intelligence, network pharmacology, and multi-omics technologies. The chapters provide in-depth analyses of the experimental and computational frameworks that underpin contemporary repurposing research, encompassing in vitro and in vivo validation alongside increasingly sophisticated in silico approaches. By integrating computational biology, bioinformatics, systems pharmacology, and machine learning with experimental sciences, the book convincingly presents drug repurposing as a truly interdisciplinary enterprise.

One of the notable strengths of this work lies in its strong translational and application-oriented focus. Beyond theoretical and methodological discussions, the volume explores high-impact therapeutic domains where drug repurposing has demonstrated exceptional promise. The detailed treatment of repurposing strategies for neurodegenerative disorders such as Parkinson’s disease and frontotemporal dementia, rheumatic autoimmune conditions, and various cancers highlights both the versatility and clinical relevance of this approach. These case studies persuasively illustrate that drug repurposing is not merely a stopgap solution, but rather a robust and sustainable pathway for tackling complex, multifactorial diseases that have long resisted conventional drug development efforts.

Dr. Talukder, together with a distinguished group of contributors, has curated a volume that will appeal to a wide and diverse readership. Students and researchers in biotechnology, pharmacology, and life sciences; computational and systems biologists; and clinicians engaged in translational and patient-centred research will all find substantial value in this work. The book strikes an effective balance between scientific rigor and accessibility, presenting complex concepts—such as molecular docking, phenotypic screening, and genomic signature matching, and data integration—with clarity, precision, and pedagogical care. Arriving at a pivotal moment in the evolution of pharmaceutical research, Trials, Tech, and Triumphs of Drug Repurposing captures both the remarkable successes and the persistent challenges that define the field. It thoughtfully addresses critical issues, including intellectual property constraints, regulatory considerations, and data integration challenges, while simultaneously highlighting emerging opportunities enabled by collaborative research frameworks, open-access databases, and advanced analytical technologies.

Written with clarity and scientific rigor, this book, containing seven chapters, will be invaluable to students, researchers, and clinicians across biotechnology, pharmacology, computational biology, and translational medicine. More than a scholarly reference, it serves as a forward-looking guide to smarter, faster, and more efficient therapeutic innovation. Dr. Talukder and his contributors are to be commended for delivering a timely, insightful, and highly relevant volume that is poised to shape the future of drug development. I wholeheartedly commend Dr. Pratik Talukder and all contributing authors for their significant contribution to the scientific literature.